5 Key Takeaways

• 1

  Patients with type 2 diabetes on SGLT2 inhibitors had a 6% surgical intervention rate compared to 12% for those on other antihyperglycemic medications.

• 2

  The study followed 218 patients with diabetes and lung nodules over 10 years, revealing a significant difference in surgical treatment rates.

• 3

  Nodule growth was observed in 14% of SGLT2 inhibitor users versus 26% of patients taking alternative diabetes medications.

• 4

  The research indicated that treating 16 patients with SGLT2 inhibitors could prevent one surgical procedure within a decade.

• 5

  The study's retrospective design limits causal interpretation and generalizability, highlighting the need for further investigation.